Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin in HER2+ Urothelial Cancer
NCT03507166Phase 2Completed
- Sponsor
- RemeGen
- Start
- Dec 2017
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in urothelial carcinoma (UC), sponsored by RemeGen. Started Dec 2017; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03507166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507166.